Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 51, Issue 6, 2012, Pages 1131-1132

  Vital, Edward M ^a,b   Dass, Shouvik ^a,b   Emery, Paul ^a,b  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

HERPES ZOSTER; HUMAN; LETTER; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE REDUCTION PROCEDURES; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84861469357     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes042     Document Type: Letter

References (4)

1. Turner-Stokes T, Lu TY, Ehrenstein MR et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology 2011;50:1401-8.
2. Vital EM, Dass S, Buch MH et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011;63:3038-47.
3. Dass S, Vital EM, Buch MH et al. Effect of concomitant DMARD on B cell depletion with rituximab in rheumatoid arthritis. EULAR; Copenhagen. Ann Rheum Dis 2009; 68(Suppl 3):579.
4. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.